Clinical effect of Saccharomyces boulardii powder combined with azithromycin sequential therapy in treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia
CHEN Qi-Fen1,2, ZHANG Yi-Wei1,2
Department of Pediatrics, Central Hospital of Jiangjin District, Chongqing 402260, China
Abstract：Objective To investigate the clinical effect of Saccharomyces boulardii powder combined with azithromycin sequential therapy in the treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia.Methods A total of 88 children with diarrhea secondary to Mycoplasma pneumoniae pneumonia between June 2015 and March 2017 were divided into control group and study group using a random number table, with 44 children in each group. The children in the control group were given routine treatment combined with azithromycin sequential therapy, and those in the study group were given oral Saccharomyces boulardii powder in addition to the treatment in the control group until the end of azithromycin sequential therapy. After the treatment ended, the two groups were compared in terms of time to improvement of clinical symptoms, length of hospital stay, clinical outcome, defecation frequency before and after treatment, condition of intestinal dysbacteriosis, and incidence of adverse events.Results Compared with the control group, the study group had significantly shorter time to improvement of clinical symptoms and length of hospital stay (P < 0.05). The study group had a significantly higher response rate than the control group (P < 0.05). On days 3 and 5 of treatment, the study group had a significant reduction in defecation frequency compared with the control group (P < 0.05). The study group had a significantly lower rate of intestinal dysbacteriosis than the control group (P < 0.05). There was no significant difference in the incidence of adverse events between the two groups (P > 0.05).Conclusions In the treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia, Saccharomyces boulardii powder combined with azithromycin sequential therapy can improve clinical symptoms, shorten the length of hospital stay, reduce defecation frequency and the incidence of intestinal dysbacteriosis, and improve clinical outcomes, and does not increase the risk of adverse events.
CHEN Qi-Fen,ZHANG Yi-Wei. Clinical effect of Saccharomyces boulardii powder combined with azithromycin sequential therapy in treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia[J]. CJCP, 2018, 20(2): 116-120.
Burr SE, Milne S, Jafali J, et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage:cross-sectional surveys in the Gambia[J]. Bull World Health Organ, 2014, 92(7):490-498.
Yakoob MY, Theodoratou E, Jabeen A, et al. Preventive zinc supplementation in developing countries:impact on mortality and morbidity due to diarrhea, pneumonia and malaria[J]. BMC Public Health, 2011, 11 Suppl 3:S23.
Schlaudecker EP, Steinhoff MC, Moore SR. Interactions of diarrhea, pneumonia, and malnutrition in childhood:recent evidence from developing countries[J]. Curr Opin Infect Dis, 2011, 24(5):496-502.
Venner M, Credner N, Lämmer M, et al. Comparison of tulathromycin, azithromycin and azithromycin-rifampin for the treatment of mild pneumonia associated with Rhodococcus equi[J]. Vet Rec, 2013, 173(16):397.
Chisti MJ, Ahmed T, Faruque AS, et al. Clinical and laboratory features of radiologic pneumonia in severely malnourished infants attending an urban diarrhea treatment center in Bangladesh[J]. Pediatr Infect Dis J, 2010, 29(2):174-177.
